BACKGROUND: Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking. METHODS: In a large, population-based natural study conducted in Guanacaste, Costa Rica, we studied a subset of 810 initially HPV-positive women with ≥ 3 years of active follow-up with ≥ 3 screening visits who had no future evidence of cervical precancer. Cervical specimens were tested for >40 HPV genotypes using a MY09/11 L1-targeted polymerase chain reaction method. RESULTS: Seventy-two prevalently-detected HPV infections (5%) in 58 women (7%) persisted until the end of the follow-up period (median duration of follow-up, 7 years) without evidence of cervical precancer. At enrollment, women with long-term persistence were more likely to have multiple prevalently-detected HPV infections (P < .001) than were women who cleared their baseline HPV infections during follow-up. In a logistic regression model, women with long-term persistence were more likely than women who cleared infections to have another newly-detected HPV infection detectable at ≥ 3 visits (odds ratio, 2.6; 95% confidence interval, 1.2-5.6). CONCLUSIONS: Women with long-term persistence of HPV infection appear to be generally more susceptible to other HPV infections, especially longer-lasting infections, than are women who cleared their HPV infections.
BACKGROUND: Detailed descriptions of long-term persistence of human papillomavirus (HPV) in the absence of cervical precancer are lacking. METHODS: In a large, population-based natural study conducted in Guanacaste, Costa Rica, we studied a subset of 810 initially HPV-positive women with ≥ 3 years of active follow-up with ≥ 3 screening visits who had no future evidence of cervical precancer. Cervical specimens were tested for >40 HPV genotypes using a MY09/11 L1-targeted polymerase chain reaction method. RESULTS: Seventy-two prevalently-detected HPV infections (5%) in 58 women (7%) persisted until the end of the follow-up period (median duration of follow-up, 7 years) without evidence of cervical precancer. At enrollment, women with long-term persistence were more likely to have multiple prevalently-detected HPV infections (P < .001) than were women who cleared their baseline HPV infections during follow-up. In a logistic regression model, women with long-term persistence were more likely than women who cleared infections to have another newly-detected HPV infection detectable at ≥ 3 visits (odds ratio, 2.6; 95% confidence interval, 1.2-5.6). CONCLUSIONS:Women with long-term persistence of HPV infection appear to be generally more susceptible to other HPV infections, especially longer-lasting infections, than are women who cleared their HPV infections.
Authors: Hans-Ulrich Bernard; Robert D Burk; Zigui Chen; Koenraad van Doorslaer; Harald zur Hausen; Ethel-Michele de Villiers Journal: Virology Date: 2010-03-05 Impact factor: 3.616
Authors: R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton Journal: Rev Panam Salud Publica Date: 1997-05
Authors: Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk Journal: J Med Virol Date: 2002-11 Impact factor: 2.327
Authors: Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-06 Impact factor: 4.254
Authors: M Concepción Bratti; Ana C Rodríguez; Mark Schiffman; Allan Hildesheim; Jorge Morales; Mario Alfaro; Diego Guillén; Martha Hutchinson; Mark E Sherman; Claire Eklund; John Schussler; Julie Buckland; Lidia A Morera; Fernando Cárdenas; Manuel Barrantes; Elmer Pérez; Thomas J Cox; Robert D Burk; Rolando Herrero Journal: Rev Panam Salud Publica Date: 2004-02
Authors: Morgan M Philbin; Amanda E Tanner; Anna DuVal; Jonathan M Ellen; Jiahong Xu; Bill Kapogiannis; Jim Bethel; J Dennis Fortenberry Journal: AIDS Behav Date: 2014-08
Authors: Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641